 Advertisement | ||||||||
 | ||||||||
|
||||||||
 |
 |
 |
 |
 |
 |
 |
||
|
From the Departments of Medicine of the University of Ottawa (Cranney), Ottawa; McMaster University (Papaioannou, Zytaruk, Adachi), Hamilton; University of Toronto (Murray), Toronto; and University of Western Ontario (Hodsman), London, Ont.; University of Calgary (Hanley), Calgary, Alta. (Hanley); and McGill University (Goltzman), Montréal, Que.
Correspondence to: Dr. Ann Cranney, Ottawa Hospital, Civic Campus, Clinical Epidemiology Program, 1053 Carling Ave., Ottawa ON K1Y 4E9; fax 613 761-5492
Abstract
Background: Human parathyroid hormone (hPTH)(1–34) was approved in 2004 for the treatment of severe osteoporosis. Members of the Osteoporosis Canada clinical guidelines committee conducted a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of hPTH for fracture prevention in postmenopausal women and men with osteoporosis.
Methods: We searched MEDLINE, EMBASE, HTA, Current Contents and the Cochrane Controlled Trials Registry for published data from 1966 to February 2005. A systematic literature search for RCTs was conducted using the Cochrane Collaborative approach. We identified 12 trials that randomly assigned patients either to hPTH or placebo or to hPTH or an active comparator and were at least 1 year in duration. Outcomes included change in bone mineral density (BMD), fractures, back pain and adverse events. Two independent reviewers abstracted data on study characteristics and outcomes.
Results: hPTH(1–34) significantly increases lumbar spine BMD, with smaller increases at the femoral neck and total hip. hPTH(1–84) significantly increases lumbar spine BMD. The data show a significant reduction in both vertebral and nonvertebral fractures with hPTH(1–34) in postmenopausal women with previous vertebral fractures. There were no data on fractures comparing the approved dose of hPTH(1–34) with active comparators.
Interpretation: There is Level I evidence that hPTH(1–34) significantly increases BMD at all skeletal sites except the radius and significantly reduces the risk of new vertebral and nonvertebral fractures in postmenopausal women with prior fractures.
Related Article
This article has been cited by other articles:
|
|
 |
|
  M. Okazaki, S. Ferrandon, J.-P. Vilardaga, M. L. Bouxsein, J. T. Potts Jr, and T. J. Gardella Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation PNAS, October 28, 2008; 105(43): 16525 - 16530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Kraenzlin Biochemical Markers of Bone Turnover and Osteoporosis Management IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Khan, A. B. Hodsman, A. Papaioannou, D. Kendler, J. P. Brown, and W. P. Olszynski Management of osteoporosis in men: an update and case example Can. Med. Assoc. J., January 30, 2007; 176(3): 345 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., December 1, 2006; 11(6): 190 - 190. [Full Text] [PDF]
|
|
|
|
 |
|
 Parathyroid hormone reduces fractures in postmenopausal women with osteoporosis BMJ, August 12, 2006; 333(7563): . [Full Text] [PDF]
|
|
|
|
|
|
A. Hodsman, A. Papaioannou, and A. Cranney Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. Can. Med. Assoc. J., July 4, 2006; 175(1): 48 - 48. [Full Text] [PDF]
|
|
| HOME | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP | SEARCH |
|
|||||
|
Copyright 1995-2006, Canadian Medical Association. All rights reserved. ISSN 1488-2329
(e) 0820-3946 (p)
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. |
|||||
